$7.1B life science takeover is scuttled: Illumina gives up on attempt to buy Grail
Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe.
Read More
